CytoDyn, Inc.

CytoDyn, Inc. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
2002-01-01
Employees
11
Market Cap
-
Website
http://www.cytodyn.com

A Phase 2 Study of Leronlimab in Combination with TAS-102 + Bevacizumab in Previously Treated Participants with MCRC

First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
60
Registration Number
NCT06699836

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

First Posted Date
2022-03-09
Last Posted Date
2022-03-09
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
56
Registration Number
NCT05271370
Locations
πŸ‡ΊπŸ‡Έ

Quest Clinical Research, San Francisco, California, United States

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

First Posted Date
2020-12-22
Last Posted Date
2024-04-11
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
56
Registration Number
NCT04678830
Locations
πŸ‡ΊπŸ‡Έ

Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States

πŸ‡ΊπŸ‡Έ

Arthritis & Rheumatic Disease Specialties, Aventura, Florida, United States

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

First Posted Date
2020-08-20
Last Posted Date
2023-03-01
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
87
Registration Number
NCT04521114
Locations
πŸ‡ΊπŸ‡Έ

Southern California Research Center, Coronado, California, United States

πŸ‡ΊπŸ‡Έ

Floridian Clinical Research, Miami Lakes, Florida, United States

πŸ‡ΊπŸ‡Έ

Center for Advanced Research & Education, Gainesville, Georgia, United States

and more 4 locations

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Phase 2
Conditions
Interventions
First Posted Date
2020-08-07
Last Posted Date
2022-07-01
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
30
Registration Number
NCT04504942
Locations
πŸ‡ΊπŸ‡Έ

Quest Clinical Research, San Francisco, California, United States

Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

First Posted Date
2020-04-15
Last Posted Date
2022-01-14
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
394
Registration Number
NCT04347239
Locations
πŸ‡ΊπŸ‡Έ

Advanced Cardiovascular, LLC, Alexander City, Alabama, United States

πŸ‡ΊπŸ‡Έ

Ohio Health, Columbus, Ohio, United States

πŸ‡ΊπŸ‡Έ

St. Barnabas, Livingston, New Jersey, United States

and more 15 locations

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

First Posted Date
2020-04-13
Last Posted Date
2023-01-04
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
86
Registration Number
NCT04343651
Locations
πŸ‡ΊπŸ‡Έ

Eisenhower Health, Rancho Mirage, California, United States

πŸ‡ΊπŸ‡Έ

University of California, Los Angeles, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Ohio Health, Columbus, Ohio, United States

and more 9 locations

A Compassionate Use Study of Leronlimab in Breast Cancer

First Posted Date
2020-03-18
Last Posted Date
2022-01-28
Lead Sponsor
CytoDyn, Inc.
Registration Number
NCT04313075

PRO 140 in Treatment-Experienced HIV-1 Subjects

Phase 2
Conditions
Interventions
First Posted Date
2019-04-04
Last Posted Date
2022-07-01
Lead Sponsor
CytoDyn, Inc.
Target Recruit Count
25
Registration Number
NCT03902522
Locations
πŸ‡ΊπŸ‡Έ

CD02_OpenLabel Investigational Site, Spokane, Washington, United States

Β© Copyright 2024. All Rights Reserved by MedPath